📊 CYTK Key Takeaways
Investment Thesis
Cytokinetics exhibits severe financial distress with negative stockholders' equity of -$659.6M, indicating liabilities exceed assets and the company is technically insolvent. Despite 376.6% revenue growth to $88M, the company burned $534.8M in free cash flow with operating losses of $612.3M, demonstrating that growth is not profitable or sustainable. With only $122.5M in cash against $2.1B in liabilities and negative operating cash flow, the company faces critical liquidity challenges requiring immediate capital raises or strategic restructuring.
CYTK Strengths
- Strong revenue growth of 376.6% year-over-year demonstrates market traction for products
- Improved net loss position with EPS decline of 24.3% suggesting operational leverage emerging
- Current ratio of 4.53x provides near-term liquidity runway despite negative equity
CYTK Risks
- Negative stockholders' equity of -$659.6M indicates technical insolvency with liabilities exceeding total assets
- Operating cash flow of -$510M and free cash flow of -$534.8M unsustainable; cash runway at current burn rate is less than 3 months
- Operating losses of $612.3M and net margins of -891.6% show core business is deeply unprofitable despite revenue growth
- Total liabilities of $2.1B against total assets of $1.4B creates structural balance sheet crisis
- High insider activity (34 Form 4 filings in 90 days) may indicate management uncertainty or strategic transitions
Key Metrics to Watch
- Cash balance trajectory and monthly burn rate - critical for survival assessment
- Path to operating profitability and gross margin expansion - essential for viability
- Capital raise announcements and dilution impact - likely necessary for continued operations
- Operating cash flow trend reversal - must turn positive to validate business model sustainability
CYTK Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 4.53x current ratio provides a solid financial cushion.
CYTK Profitability Ratios
CYTK vs Healthcare Sector
How CYTOKINETICS INC compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CYTK Balance Sheet & Liquidity
CYTK 5-Year Financial Trend
5-Year Trend Summary: CYTOKINETICS INC's revenue has grown significantly by 25% over the 5-year period, indicating strong business expansion. The most recent EPS of $-5.45 indicates the company is currently unprofitable.
CYTK Growth Metrics (YoY)
CYTK Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $463.0K | -$134.4M | $-1.36 |
| Q2 2025 | $249.0K | -$134.4M | $-1.12 |
| Q1 2025 | $835.0K | -$135.6M | $-1.33 |
| Q3 2024 | $378.0K | -$128.6M | $-1.35 |
| Q2 2024 | $249.0K | -$128.6M | $-1.31 |
| Q1 2024 | $835.0K | -$131.3M | $-1.33 |
| Q3 2023 | $378.0K | -$19.8M | $-1.35 |
| Q2 2023 | $867.0K | -$19.8M | $-0.23 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CYTK Capital Allocation
CYTK SEC Filings
Access official SEC EDGAR filings for CYTOKINETICS INC (CIK: 0001061983)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CYTK
What is the AI rating for CYTK?
CYTOKINETICS INC (CYTK) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CYTK's key strengths?
Strong revenue growth of 376.6% year-over-year demonstrates market traction for products. Improved net loss position with EPS decline of 24.3% suggesting operational leverage emerging.
What are the risks of investing in CYTK?
Negative stockholders' equity of -$659.6M indicates technical insolvency with liabilities exceeding total assets. Operating cash flow of -$510M and free cash flow of -$534.8M unsustainable; cash runway at current burn rate is less than 3 months.
What is CYTK's revenue and growth?
CYTOKINETICS INC reported revenue of $88.0M.
Does CYTK pay dividends?
CYTOKINETICS INC does not currently pay dividends.
Where can I find CYTK SEC filings?
Official SEC filings for CYTOKINETICS INC (CIK: 0001061983) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CYTK's EPS?
CYTOKINETICS INC has a diluted EPS of $-6.54.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.